The 2027 Nashville Hematology Conference (NHC 2027) will convene over 75 leading national experts, rising faculty, and community-based hematology clinicians for two days of CE-accredited education. Designed for practicing physicians and multidisciplinary oncology professionals, the conference addresses current standards, evolving treatment strategies, practical implementation challenges, and future directions across hematologic malignancies.
*Agenda is subject to change.
Poster Session & Welcome Reception
Benign Hematology
Pre-Malignant Hematologic Disorders
Standard of Care in Lymphoid Malignancies: What’s New in 2027?
What’s New in Myeloid Malignancies
Standard Treatment of Myeloma in 2027
Debates
Keynote Speaker
MRD Across Hematologic Malignancies
Pitfalls in the Treatment of Myeloid Malignancies
Tool Kit for T-Cell Directed Therapies
Tools for Tomorrow’s Oncologist – Advancing Community Care
Future Landscapes
Debates
Sponsored by Johnson & Johnson and Bristol Myers Squibb
Industry attendance for this event is exclusive to only the sponsors of the Poster Session & Welcome Reception
Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 2L+ FL
Speaker: Jonathan Abbas, MD
Sponsored by Genmab and AbbVie
Industry attendance is limited to breakfast industry symposium sponsors only
Chairs:
Jesús Berdeja, MD (Greco-Hainsworth Tennessee Oncology Centers for Research)
Andrew Kuykendall, MD (Moffitt Cancer Center)
Joanna Rhodes, MD, MSCE (Rutgers Cancer Institute of New Jersey)
8:50 AM
Evolving Diagnostics in Iron Deficiency Anemia
Angela Weyand, MD (University of Michigan)
8:58 AM
The Bleeding Patient Consult
Michelle Chi, MD (Vanderbilt Health)
9:06 AM
New Developments in Sickle Cell Disease
Scott Peslak, MD, PhD (University of Pennsylvania)
9:14 AM
TTP/HUS
Spero Cataland, MD (The Ohio State University)
9:22 AM
Update in Venous Thromboembolism
Adam Cuker, MD, MS (University of Pennsylvania)
9:30 AM
Panel Discussion + Q&A
9:48 AM
MGUS/ SMM
Caitlin Costello, MD (University of California San Diego)
9:56 AM
CHIP/CCUS
Zhuoer Xie, MD, MS (Moffitt Cancer Center)
10:04 AM
MBL: Implications on Infectious Risk
Erin Mulvey, MD, MSCI (Weill Cornell Medicine)
10:12 AM
Panel Discussion + Q&A
11:00 AM
Debate: Single Agent Monotherapy vs Fixed Duration Combos in Frontline CLL
Moderator: Matthew Lunning, DO, FACP (University of Nebraska)
Adam Kittai, MD (Mount Sinai Health System)
Callie Coombs, MD (University of California Irvine)
11:20 AM
Multiple Myeloma
Amrita Krishnan, MD, FACP (City of Hope)
11:28 AM
Diffuse Large B-Cell Lymphoma
Ryan Lynch, MD (Fred Hutch Cancer Center)
11:36 AM
Hodgkin’s Lymphoma
Boyu Hu, MD (Huntsman Cancer Institute)
11:44 AM
Indolent Lymphomas
Elizabeth Brém, MD (University of California Irvine)
11:52 AM
Panel Discussion + Q&A
Reignite the Spark: Clinical Conversations about Jaypirca® (pirtobrutinib)
Speaker: Callie Coombs, MD (University of California Irvine)
Sponsored by Lilly
Industry attendance is limited to lunch industry symposium sponsor only
1:40 PM
Myeloproliferative Neoplasms
Gabriela Hobbs, MD (Massachusetts General Hospital)
1:48 PM
Myelofibrosis
John Mascarenhas, MD (Mount Sinai Health System)
1:56 PM
Chronic Myeloid Leukemia
Srinivas Tantravahi, MBBS, MRCP (Huntsman Cancer Institute)
2:04 PM
Myelodysplastic Syndromes
Anthony Hunter, MD (Winship Cancer Institute of Emory University)
2:12 PM
Panel Discussion + Q&A
2:32 PM
Defining High-Risk Disease in Lymphoid Malignancies
Jeremy Abramson, MD (Harvard Medical School)
2:40 PM
High-Risk Multiple Myeloma: Time For a Paradigm Change?
Natalie Callander, MD (University of Wisconsin)
2:48 PM
TP53-Mutated AML and MDS
David Sallman, MD (Moffitt Cancer Center)
2:56 PM
Panel Discussion + Q&A
3:45 PM
Multiple Myeloma in Patients with Frailty or Comorbidities
Rahul Banerjee, MD, FACP (Fred Hutch Cancer Center)
3:53 PM
How To Tackle Curative Intent in Lymphoma Patients With Cardiac Comorbidities
Sarah Rutherford, MD (Weill Cornell Medicine)
4:01 PM
MDS/MPN Overlap Syndromes
Eric Padron, MD (Moffitt Cancer Center)
4:09 PM
Debate: Intensive vs Less Intensive Induction For The Treatment of Older, But Fit, Patients With Newly Diagnosed AML
Moderator: Matthew Lunning, DO, FACP (University of Nebraska)
Dan Pollyea, MD, MS (University of Colorado School of Medicine)
Jeffrey Lancet, MD (Moffitt Cancer Center)
4:29 PM
Panel Discussion + Q&A
LYNOZYFIC in The Treatment of 5L+ Relapsed/Refractory Multiple Myeloma
Speaker: Sherif Farag, MD (Community Health Network MD Anderson Cancer Center Stem Cell Transplant & Cellular Therapy Institute)
Sponsored by Regeneron
Industry attendance is limited to breakfast industry symposium sponsor only
Chairs:
Jesús Berdeja, MD (Greco-Hainsworth Tennessee Oncology Centers for Research)
Andrew Kuykendall, MD (Moffitt Cancer Center)
Joanna Rhodes, MD, MSCE (Rutgers Cancer Institute of New Jersey)
8:45 AM
MRD in AML: Who, What, When, and How?
Rory Shallis, MD (Moffitt Cancer Center)
8:53 AM
Defining The Value of uMRD in CLL
Chaitra Ujjani, MD (Fred Hutch Cancer Center)
9:01 AM
MRD in Multiple Myeloma: How, When and Why?
Noopur Raje, MD (Massachusetts General Hospital)
9:09 AM
ctDNA in Lymphoma
Sairah Ahmed, MD (MD Anderson Cancer Center)
9:17 AM
Debate: Is Monotherapy Maintenance Until Progression The Optimal Approach To Maintenance Therapy in Multiple Myeloma in The Era of Quadruplet Induction?
Moderator: Matthew Lunning, DO, FACP (University of Nebraska)
Peter Voorhees, MD (Atrium Health Levine Cancer Institute)
Faith Davies, MD (NYU Langone Health)
9:37 AM
Panel Discussion + Q&A
9:55 AM
Multiple Myeloma
Mansi Shah, MD (Rutgers Cancer Institute of New Jersey)
10:03 AM
CLL
Jacqueline Barrientos, MD, MS (Mount Sinai Health System)
10:11 AM
Indolent Lymphomas
Krish Patel, MD (Sarah Cannon Research Institute)
10:19 AM
Acute Myeloid Leukemia
Rami Komrokji, MD (Moffitt Cancer Center)
10:27 AM
Panel Discussion + Q&A
11:15 AM
CAR-T in Multiple Myeloma
Krina Patel, MD (MD Anderson Cancer Center)
11:23 AM
CAR-T in Non-Hodgkin’s Lymphoma
Elise Chong, MD (University of Pennsylvania)
11:31 AM
Bispecifics in Multiple Myeloma
Susan Bal, MD (University of Alabama Birmingham)
11:39 AM
Bispecifics in Lymphomas
Tycel Phillips, MD (City of Hope)
11:47 AM
Managing Acute Toxicities with Cellular and T-cell Redirecting Therapies
Babis Andreadis, MD, MS (University of California San Francisco)
11:55 AM
Panel Discussion + Q&A
Optimal Sequencing in RRMM
Peter Voorhees, MD (Atrium Health Levine Cancer Institute)
Sponsored by Kite and Arcellx and Johnson & Johnson
Industry attendance is limited to lunch symposium sponsors only
1:55 PM
Utilizing Remote Consultation To Optimize Patient Care in The Community Setting
Jennifer Green, MD (Tennessee Oncology)
2:03 PM
Utilizing Frailty Indexes
Reena Jayani-Kosarzycki, MD, MSCI (Vanderbilt Health)
2:11 PM
Bringing Bispecifics to the Community
Tara Graff, DO, MS (Mission Cancer + Blood)
2:19 PM
Managing Long-Term Toxicities With Cellular and T-cell Redirecting Therapies
Adam Cohen, MD (University of Pennsylvania)
2:27 PM
Panel Discussion +Q&A
3:17 PM
Multiple Myeloma
Ajay Nooka, MD, MPH (Winship Cancer Institute of Emory University)
3:25 PM
CLL
Deborah Stephens, DO (University of North Carolina School of Medicine)
3:33 PM
Non-Hodgkin’s Lymphoma
Sameh Gaballa, MD (Moffitt Cancer Center)
3:41 PM
AML+MDS
Uma Borate, MBBS (The Ohio State University)
3:49 PM
MPNs +SM+CML
Kristen Pettit, MD (University of Michigan)
3:57 PM
Q&A
*Agenda is subject to change.
Experience Nashville, TN